101 related articles for article (PubMed ID: 21816748)
1. Potential withdrawal of bevacizumab for the treatment of breast cancer.
Jones A; Ellis P
BMJ; 2011 Aug; 343():d4946. PubMed ID: 21816748
[No Abstract] [Full Text] [Related]
2. FDA committee votes to withdraw bevacizumab for breast cancer.
Lenzer J
BMJ; 2011 Jul; 343():d4244. PubMed ID: 21729988
[No Abstract] [Full Text] [Related]
3. Bevacizumab recommendation highlights difficulties.
Printz C
Cancer; 2011 Nov; 117(22):5025. PubMed ID: 22052367
[No Abstract] [Full Text] [Related]
4. Lessons from the other side of the Atlantic.
Prescrire Int; 2012 Jun; 21(128):165-6. PubMed ID: 22822597
[TBL] [Abstract][Full Text] [Related]
5. Avastin withdrawal symptoms.
Lynce F; Swain SM
Expert Opin Pharmacother; 2012 Feb; 13(3):293-8. PubMed ID: 22263961
[No Abstract] [Full Text] [Related]
6. FDA pulls approval for avastin in breast cancer.
Rose S
Cancer Discov; 2011 Dec; 1(7):OF1-2. PubMed ID: 22586694
[TBL] [Abstract][Full Text] [Related]
7. Trials of bevacizumab in breast cancer--a safety review.
Kümler I; Nielsen DL
Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S37-48. PubMed ID: 21663533
[TBL] [Abstract][Full Text] [Related]
8. Reversible posterior leukoencephalopathy syndrome and bevacizumab in breast cancer.
Sclafani F; Giuseppe G; Mezynksi J; Collins C; Crown J
J Clin Oncol; 2012 Sep; 30(26):e257-9. PubMed ID: 22649141
[No Abstract] [Full Text] [Related]
9. Avastin for breast cancer, 2005-2011: requiescat in pacem?
Burstein HJ
J Natl Compr Canc Netw; 2011 Dec; 9(12):1321-3. PubMed ID: 22157551
[No Abstract] [Full Text] [Related]
10. FDA panel votes to pull Avastin in breast cancer, again.
Ratner M
Nat Biotechnol; 2011 Aug; 29(8):676. PubMed ID: 21822226
[No Abstract] [Full Text] [Related]
11. Retrobulbar optic neuritis in a bevacizumab-treated patient with metastatic breast cancer.
Zhou Y; Zhang Y; Yang X; Fan L; Jiang J
Breast J; 2012 Sep; 18(5):502-3. PubMed ID: 22891618
[No Abstract] [Full Text] [Related]
12. Avastin's uncertain future in breast cancer treatment.
Twombly R
J Natl Cancer Inst; 2011 Mar; 103(6):458-60. PubMed ID: 21393607
[No Abstract] [Full Text] [Related]
13. Oncologic drugs advisory committee recommends withdrawing approval for bevacizumab use in breast cancer treatment.
Future Oncol; 2010 Sep; 6(9):1374. PubMed ID: 20931736
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO.
Pivot X; Schneeweiss A; Verma S; Thomssen C; Passos-Coelho JL; Benedetti G; Ciruelos E; von Moos R; Chang HT; Duenne AA; Miles DW
Eur J Cancer; 2011 Nov; 47(16):2387-95. PubMed ID: 21757334
[TBL] [Abstract][Full Text] [Related]
15. Making genuine progress against metastatic breast cancer.
Lyman GH; Burstein HJ; Buzdar AU; D'Agostino R; Ellis PA
J Clin Oncol; 2012 Oct; 30(28):3448-51. PubMed ID: 22927527
[No Abstract] [Full Text] [Related]
16. Avastin saga reveals debate over clinical trial endpoints.
Sharma SP
J Natl Cancer Inst; 2012 Jun; 104(11):800-1. PubMed ID: 22673590
[No Abstract] [Full Text] [Related]
17. Reputation and precedent in the bevacizumab decision.
Carpenter D; Kesselheim AS; Joffe S
N Engl J Med; 2011 Jul; 365(2):e3. PubMed ID: 21707383
[No Abstract] [Full Text] [Related]
18. Avastin hearing leads to more uncertainty over drug's future.
Goozner M
J Natl Cancer Inst; 2011 Aug; 103(15):1148-50. PubMed ID: 21768534
[No Abstract] [Full Text] [Related]
19. Bevacizumab-associated hyperlipoproteinemia type IIb in a patient with advanced invasive-ductal breast cancer.
Joerger M; Riesen WF; Thürlimann B
J Oncol Pharm Pract; 2011 Sep; 17(3):292-4. PubMed ID: 20667851
[TBL] [Abstract][Full Text] [Related]
20. Success of bevacizumab trials raises questions for future studies.
Tuma RS
J Natl Cancer Inst; 2005 Jul; 97(13):950-1. PubMed ID: 15998941
[No Abstract] [Full Text] [Related]
[Next] [New Search]
